Hercules Capital, Inc. (HTGC) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Hercules Capital, Inc. is an internally managed, non-diversified closed-end management investment company regulated as a Business Development Company (BDC) under the Investment Company Act of 1940. The Company focuses on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in technology and life sciences industries. As of March 31, 2026, the Company had 187.2 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Investment Income | $141.5 million | $119.5 million |
| Net Investment Income | $88.1 million | $77.5 million |
| Net Increase in Net Assets from Operations | $42.5 million | $50.3 million |
| Net Asset Value (NAV) per Share | $11.90 | $11.55 |
| Total Assets | $4.83 billion | $4.58 billion |
| Total Debt (Carrying Value) | $2.54 billion | $2.29 billion |
| Cash and Cash Equivalents | $42.4 million | $57.0 million |
| Weighted Average Cost of Debt | 5.1% | 4.9% |
| Portfolio Yield (Core) | 12.2% | 12.6% |
Material Changes vs. Prior Period
- Investment Income Growth: Total investment income increased by 18.4% year-over-year, driven primarily by a larger weighted average principal outstanding, partially offset by a slight decrease in core yield.
- Unrealized Depreciation: The Company recorded a net change in unrealized depreciation of $45.0 million in Q1 2026, compared to $25.6 million in Q1 2025. This increase was primarily due to widening credit spreads on debt investments, compression of market multiples for private equity holdings, and depreciation of public equity/warrant holdings.
- Debt Expansion: Total debt outstanding increased by approximately $253 million compared to the prior year quarter. This included the issuance of $300 million in 5.350% Notes due 2029 and increased utilization of credit facilities, offset by the full repayment of the March 2026 A and B Notes ($100 million total).
- Operating Expenses: Net operating expenses rose to $53.4 million from $42.1 million, largely due to higher interest expense on increased debt levels and higher employee compensation.
Guidance, Outlook, and Risks
- Portfolio Composition: The portfolio remains heavily concentrated in Application Software (23.6%), Drug Discovery & Development (23.1%), and Healthcare Services (18.9%).
- Liquidity: As of March 31, 2026, the Company had approximately $454.5 million in available liquidity, including cash and available borrowing capacity under credit facilities. The Company maintains an asset coverage ratio of 199.6% (excluding SBA debentures), well above the 150% regulatory minimum.
- Distributions: The Board declared a total distribution of $0.47 per share for the quarter (comprising a $0.40 base and $0.07 supplemental). A subsequent distribution of $0.47 per share was declared on April 29, 2026, for payment in May 2026.
- Risks: Key risks include the potential failure of significant portfolio investments (seven companies represent >5% of net assets), interest rate volatility (though 98% of debt has floating rates with floors), and macroeconomic factors affecting the technology and life sciences sectors.
Investor Verification Checklist
- Verify the impact of the $45 million unrealized depreciation on the Company's NAV and future earnings potential.
- Review the concentration risk in the top seven portfolio companies, which collectively represent a significant portion of net assets.
- Confirm the sustainability of the 12.2% Core Yield given the competitive lending environment and potential spread widening.
- Monitor the utilization of the $397.4 million in unfunded commitments and the Company's ability to deploy capital efficiently.
- Assess the Company's leverage profile, specifically the 5.1% weighted average cost of debt relative to portfolio yields.